Ningbo Sanxing Medical ElectricLtd And 2 Top Insider Picks For Growth
Reviewed by Simply Wall St
As global markets respond to rising U.S. Treasury yields and the Federal Reserve's cautious approach to rate cuts, investors are increasingly focusing on growth stocks that have shown resilience in these fluctuating conditions. In this context, companies with high insider ownership can be particularly appealing as they often signal confidence from those who know the business best, making them intriguing options for those seeking potential growth opportunities amidst economic uncertainties.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 17.3% | 21.1% |
| People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
| Medley (TSE:4480) | 34% | 30.4% |
| Seojin SystemLtd (KOSDAQ:A178320) | 30.7% | 49.1% |
| Findi (ASX:FND) | 35.8% | 64.8% |
| Alkami Technology (NasdaqGS:ALKT) | 11.2% | 101.9% |
| Adveritas (ASX:AV1) | 21.2% | 144.2% |
| Plenti Group (ASX:PLT) | 12.8% | 107.6% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 13.9% | 95% |
| UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
We're going to check out a few of the best picks from our screener tool.
Ningbo Sanxing Medical ElectricLtd (SHSE:601567)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution and utilization systems in China and internationally, with a market cap of CN¥43.52 billion.
Operations: The company's revenue segments include the manufacturing and sale of power distribution and utilization systems both domestically and internationally.
Insider Ownership: 23.8%
Earnings Growth Forecast: 21.2% p.a.
Ningbo Sanxing Medical Electric Ltd. is trading 24.8% below its estimated fair value, offering potentially good relative value compared to peers and the industry. The company reported significant revenue growth for the nine months ended September 2024, with sales reaching CNY 10.43 billion from CNY 8.34 billion a year ago, and net income increasing to CNY 1.82 billion from CNY 1.49 billion, reflecting strong earnings performance despite an unstable dividend track record.
- Delve into the full analysis future growth report here for a deeper understanding of Ningbo Sanxing Medical ElectricLtd.
- In light of our recent valuation report, it seems possible that Ningbo Sanxing Medical ElectricLtd is trading behind its estimated value.
Jiayou International LogisticsLtd (SHSE:603871)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Jiayou International Logistics Co., Ltd, with a market cap of CN¥19.34 billion, provides domestic and international multimodal transportation, logistics infrastructure investment and operation, and supply chain trade through its subsidiaries.
Operations: Jiayou International Logistics Co., Ltd generates revenue through its services in domestic and international multimodal transportation, logistics infrastructure investment and operation, as well as supply chain trade.
Insider Ownership: 19.3%
Earnings Growth Forecast: 24.3% p.a.
Jiayou International Logistics Ltd. is trading 43.1% below its estimated fair value, presenting a strong relative value opportunity. The company reported robust revenue growth for the nine months ending September 2024, with sales rising to CNY 6.54 billion from CNY 5.10 billion and net income increasing to CNY 1.09 billion from CNY 754.75 million year-on-year, despite a dividend yield of 2.96% not being well-covered by free cash flows.
- Dive into the specifics of Jiayou International LogisticsLtd here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential undervaluation of Jiayou International LogisticsLtd shares in the market.
Changchun BCHT Biotechnology (SHSE:688276)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical company involved in the research, development, production, and sale of human vaccines both in China and internationally, with a market cap of CN¥10.91 billion.
Operations: The company's revenue is primarily derived from its biotechnology segment, amounting to CN¥1.61 billion.
Insider Ownership: 32%
Earnings Growth Forecast: 40.8% p.a.
Changchun BCHT Biotechnology is trading at a favorable valuation with a price-to-earnings ratio of 25.4x, which is below the CN market average. Despite recent earnings declines, with nine-month sales at CNY 1.03 billion compared to CNY 1.24 billion last year, the company's revenue and earnings are forecasted to grow significantly faster than the market over the next three years. However, its dividend yield of 0.59% is not well-covered by free cash flows.
- Click to explore a detailed breakdown of our findings in Changchun BCHT Biotechnology's earnings growth report.
- According our valuation report, there's an indication that Changchun BCHT Biotechnology's share price might be on the cheaper side.
Turning Ideas Into Actions
- Navigate through the entire inventory of 1529 Fast Growing Companies With High Insider Ownership here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:603871
Jiayou International LogisticsLtd
Engages in the provision of domestic and international multimodal transportation, logistics infrastructure investment, and operation and supply chain trade.
Very undervalued with high growth potential.
